Short QT syndrome

G Medical Innovations to announce receiving of 2 (two) granted patents from the USPTO for its Prizma care and other physiological sensors developed by the company.

Retrieved on: 
Monday, December 5, 2022
Degenerative disease, Cardiovascular disease, Temperature, Light, Reading, Patent, Algorithm, Pressure, Diabetes, CVD, Telehealth, Short QT syndrome, Dr. G: Medical Examiner, Software patents under United States patent law, Smartphone, Vital signs, MHealth, Patient, Medical device, Prizma

This patent integrates sensing mechanism that allows the monitoring system to analyze the sensing condition (pressure, ambient temperature, light, conductivity, etc.)

Key Points: 
  • This patent integrates sensing mechanism that allows the monitoring system to analyze the sensing condition (pressure, ambient temperature, light, conductivity, etc.)
  • This allows higher and more accurate sensing that results in reducing false positive reading including false alarms.
  • This will allow the company to increase the attractiveness of its products, boost its market activity and achieve a bigger market share.
  • G Medical Innovations Holdings Ltd. is a healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms.

G Medical Innovations Announces First Half 2022 Financial Results and Provides Business Update

Retrieved on: 
Friday, November 18, 2022
COVID-19, Growth, Degenerative disease, Short QT syndrome, Patient, Cardiovascular disease, Government, Electrocardiography, Vital signs, Annual report, Telehealth, Research, Diabetes, PCR, Security (finance), Prizma, Special-purpose acquisition company, MHealth, Risk, Smartphone, Collection, Dr. G: Medical Examiner, Animal, Life insurance, Medical device, Rope

Irvine, CA, Nov. 18, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (G Medical or the Company), an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms, today announced its financial results and provided a business update for the six months ended June 30, 2022.

Key Points: 
  • Irvine, CA, Nov. 18, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (G Medical or the Company), an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms, today announced its financial results and provided a business update for the six months ended June 30, 2022.
  • Cash and cash equivalents as of June 30, 2022, were $1,509 thousand, compared to $6,034 thousand as of December 31, 2021.
  • About G Medical Innovations Holdings Ltd.
    G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms.
  • The Companys actual results and financial condition may differ materially from those indicated in the forward-looking statements.

G Medical Innovations is introducing a Monkeypox consumer home health test kit, along with 30 new direct to consumer home health testing kits with 24 to 48 hours results

Retrieved on: 
Thursday, October 6, 2022
MHealth, Short QT syndrome, CLIA, Cardiovascular disease, Pharmacy, Smartphone, Patient, Privacy, Dr. G: Medical Examiner, Private Securities Litigation Reform Act, Degenerative disease, Company, Saliva, CEO, CVD, Diabetes, Telehealth, Vital signs, Solution, Algorithm, Medical device, Prizma

IRVINE, California, Oct. 06, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the “Company” or “G Medical Innovations”) today announced that its wholly owned subsidiary, G. Medical Health and Wellness, Inc., has developed 31 different at-home health tests kits that are expected to be available to consumers during Q4-2022 through online and later popular big-box retail sites and pharmacies across the United States.

Key Points: 
  • Consumers should expect to pay anywhere from$50to$260depending on the tests complexity.
  • As telehealth and telemedicine industry pioneers, the management ofG Medical Innovationshas been offering patient home care monitoring and service for over 30 years.
  • G Medical Innovations Holdings Ltd.is a healthcare company engaged in the development of next-generation mHealth and telemedicine solutions and monitoring service platforms.
  • References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.

G Medical Innovations is introducing affordable, new direct to consumer home health testing kits with quick results

Retrieved on: 
Wednesday, July 13, 2022
Online, Telehealth, Security (finance), U.S. Securities and Exchange Commission, Pharmacy, Dr. G: Medical Examiner, Privacy, Solution, Diabetes, Food, Vital signs, Company, Wellness, CLIA, Patient, CEO, Algorithm, GLOBE, Cardiovascular disease, MHealth, Private Securities Litigation Reform Act, Glycated hemoglobin, CVD, Short QT syndrome, Smartphone, Saliva, Degenerative disease, HPV, NASDAQ, Medical device, Prizma

IRVINE, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the “Company” or “G Medical Innovations”) today announced that its wholly owned subsidiary, G. Medical Health and Wellness, Inc., has developed seven different at-home tests that are expected to be available to consumers during Q3-2022 through popular big-box retail sites, pharmacies and Online. The tests developed for health issues ranging from food sensitivity, Indoor/Outdoor allergies, HPV, thyroid functioning, testosterone levels, and the hemoglobin A1C test, with results going directly to the user within days.

Key Points: 
  • The tests developed for health issues ranging from food sensitivity, Indoor/Outdoor allergies, HPV, thyroid functioning, testosterone levels, and the hemoglobin A1C test, with results going directly to the user within days.
  • This will allow them to quickly begin making any necessary health changes or follow up health care visits, said Dr. Yacov Geva, CEO of G Medical Innovations.
  • As Telehealth and Telemedicine industry pioneers, the management of G Medical Innovations has been offering patient home care monitoring and service for over 30 years.
  • G Medical Innovations Holdings Ltd. is a healthcare company engaged in the development of next-generation mHealth and telemedicine solutions and monitoring service platforms.

G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) Announces Share Repurchase Program

Retrieved on: 
Friday, May 20, 2022
Diabetes, Smartphone, MHealth, ERT (company), Vital signs, ECG, Company, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Share repurchase, Patient, NASDAQ, Solution, Degenerative disease, Risk, CVD, Short QT syndrome, Telehealth, Compliance, SEC, Cardiovascular disease, Annual report, GLOBE, Security (finance), Medical device, Prizma

Irvine, California, May 20, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd.(NASDAQ: GMVD) (theCompany) today announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the Company's ordinary shares (the Repurchase Plan).

Key Points: 
  • Irvine, California, May 20, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd.(NASDAQ: GMVD) (theCompany) today announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the Company's ordinary shares (the Repurchase Plan).
  • The Company may repurchase all or a portion of the authorized repurchase amount.
  • The Repurchase Plan does not obligate the Company to repurchase any specific number of the ordinary shares and may be suspended or terminated at any time at managements discretion.
  • G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms.

DGAP-News: G Medical Innovations (NASDAQ: GMVD) Provides Update Regarding its Forecast for Q1 2022 Revenues

Retrieved on: 
Thursday, May 19, 2022
Diabetes, Smartphone, MHealth, ERT (company), Vital signs, ECG, Company, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Patient, NASDAQ, Solution, Degenerative disease, Government, Risk, CVD, COVID-19, COVID-19 testing, Short QT syndrome, Telehealth, Congress, SEC, LLC, Security (finance), CA, Cardiovascular disease, Annual report, Pharmaceutical industry, Prizma

Irvine, CA May 18, 2022 G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the Company), today announced that it will not meet its forecast of $30 million in revenues for the first quarter of 2022.

Key Points: 
  • Irvine, CA May 18, 2022 G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the Company), today announced that it will not meet its forecast of $30 million in revenues for the first quarter of 2022.
  • The Company plans to announce the final revenues numbers for the first quarter of 2022 as part of its financial results release for the first six months of 2022.
  • G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms.
  • References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.

DGAP-News: G Medical Innovations Holdings Ltd Announces Closing of $8 Million Private Placement

Retrieved on: 
Wednesday, April 20, 2022
Dr. G: Medical Examiner, Short QT syndrome, MHealth, ECG, Vital signs, Degenerative disease, U.S. Securities and Exchange Commission, Security (finance), NASDAQ, Private Securities Litigation Reform Act, GLOBE, Sale, Risk, Securities Act of 1933, Patient, TEL, Review, Smartphone, Telehealth, Company, Solution, SEC, NEW, Diabetes, CVD, Exercise, Cardiovascular disease, Medical device, Prizma

TEL AVIV and NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the 'Company'), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, today announced that it has closed its previously announced private placement with a healthcare-focused institutional investor to purchase 5,000,000 ordinary shares (or ordinary shares equivalents), and warrants to purchase up to an aggregate of 6,250,000 ordinary shares, at a combined purchase price of $1.50 per ordinary share and related warrant, for gross proceeds of approximately $7.5 million. The warrants have an exercise price of $1.50 per ordinary share, are immediately exercisable, and expire five years from issuance.

Key Points: 
  • The warrants have an exercise price of $1.50 per ordinary share, are immediately exercisable, and expire five years from issuance.
  • G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms.
  • Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services.
  • For example, G Medical is using forward-looking statements when it discusses the expected use of proceeds.

(Correction) G Medical Innovations Holdings Ltd Announces $7.5 Million Private Placement

Retrieved on: 
Monday, April 18, 2022
ECG, Dr. G: Medical Examiner, Short QT syndrome, MHealth, Vital signs, Degenerative disease, U.S. Securities and Exchange Commission, Security (finance), NASDAQ, Private Securities Litigation Reform Act, GLOBE, Sale, Securities Act of 1933, Patient, TEL, Smartphone, Telehealth, Company, Solution, SEC, NEW, United, Diabetes, CVD, Exercise, Cardiovascular disease, Medical device, Prizma

The gross proceeds from the private placement are expected to be $7.5 million before deducting placement agent fees and other offering expenses.

Key Points: 
  • The gross proceeds from the private placement are expected to be $7.5 million before deducting placement agent fees and other offering expenses.
  • The private placement is expected to close on or about April 20, 2022, subject to the satisfaction of customary closing conditions.
  • G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms.
  • For example, G Medical is using forward-looking statements when it discusses the closing of the private placement and the expected use of proceeds.

DGAP-News: G Medical Innovations Holdings Ltd Announces $7.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Monday, April 18, 2022
ECG, Dr. G: Medical Examiner, Short QT syndrome, MHealth, Vital signs, Degenerative disease, U.S. Securities and Exchange Commission, Security (finance), NASDAQ, Private Securities Litigation Reform Act, GLOBE, Sale, Risk, Securities Act of 1933, Patient, TEL, Smartphone, Telehealth, Company, Solution, SEC, NEW, Diabetes, CVD, Exercise, Cardiovascular disease, Medical device, Nasdaq, Prizma

TEL AVIV and NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company"), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor to purchase 5,000,000 ordinary shares (or ordinary shares equivalents) in a private placement priced at-the-market under Nasdaq rules. The Company will also issue to the investor warrants to purchase up to an aggregate of 6,250,000 ordinary shares. The purchase price for one ordinary share and one warrant to purchase one ordinary share is $1.50. The warrants have an exercise price of $1.50 per ordinary share, will be immediately exercisable, and will expire five years from issuance.

Key Points: 
  • The gross proceeds from the private placement are expected to be $7.5 million before deducting placement agent fees and other offering expenses.
  • The private placement is expected to close on or about April 20, 2022, subject to the satisfaction of customary closing conditions.
  • G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms.
  • For example, G Medical is using forward-looking statements when it discusses the closing of the private placement and the expected use of proceeds.

DGAP-News: CORRECTING and REPLACING G Medical Innovations takes aggressive approach to protect shareholders by combatting naked shorting of GMVD shares with an investigation to end the criminal activity

Retrieved on: 
Friday, April 1, 2022
Company, Private Securities Litigation Reform Act, Degenerative disease, Telehealth, NASDAQ, Cardiology, ECG, Form, Smartphone, Growth, McDade, Patient, Vital signs, CVD, SEC, Risk, Hospital, FINRA, Dr. G: Medical Examiner, Cardiovascular disease, U.S. Securities and Exchange Commission, Diabetes, MHealth, COVID-19, SEC filing, Solution, Short QT syndrome, Security (finance), Pharmaceutical industry, Medical device, Prizma

This release issued on March 30, 2022 is being replaced with the following corrected version due to multiple revisions.

Key Points: 
  • This release issued on March 30, 2022 is being replaced with the following corrected version due to multiple revisions.
  • (NASDAQ: GMVD) takes aggressive approach to protect shareholders by combatting naked shorting of GMVD shares with an investigation to end the criminal activity and ensure perpetrators will face aggressive legal action in the interest of protecting shareholders.
  • (NASDAQ: GMVD) announced that it has investigated aggressive naked short sales of its stock and is confident that it has identified the perpetrators of this illegal activity.
  • The company will defend its shareholders by taking all regulatory and legal action against this criminal activity.